In the absence of metabolic activation, neither Spironolactone tablets nor potassium canrenoate has been shown to be mutagenic in mammalian tests In a three-litter reproduction study in which female rats received dietary doses of 15 and 50 mg Spironolactone tablets/kg/day, there were no effects on mating and fertility, but there was a small increase in incidence of stillborn pups at 50 mg/kg/day. Monitor lithium levels periodically when Spironolactone tablets are coadministered In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. LVEF denotes left ventricular ejection fraction, Ser Creatinine denotes serum creatinine, Cr Clearance denotes creatinine clearance, and ACEI denotes angiotensin-converting enzyme inhibitor.The dose response of Spironolactone for hypertension has not been well characterized. Available for Android and iOS devices. Rarely, instances of hyponatremia, hyperkalemia, or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage.
These considerations may guide selection of therapy.Spironolactone tablets are indicated for the management of edema in the following settings:Because it increases serum potassium, Spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia.Spironolactone tablets are indicated in the following settings:Spironolactone tablets can be taken with or without food, but should be taken consistently with respect to food In patients with serum potassium ≤5.0 mEq/L and eGFR >50 mL/min/1.73 m², initiate treatment at 25 mg once daily.
By competing with aldosterone for receptor sites, Spironolactone provides effective therapy for the edema and ascites in those conditions.Spironolactone counteracts secondary aldosteronism induced by the volume depletion and associated sodium loss caused by active diuretic therapy.The mean time to reach peak plasma concentration of Spironolactone and the active metabolite, canrenone, in healthy volunteers is 2.6 and 4.3 hours, respectively.Spironolactone and its metabolites are more than 90% bound to plasma proteins.The mean half-life of Spironolactone is 1.4 hour. For patients who are considered unsuitable for surgery, Spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.Tablets: 25 mg white, round, unscored, debossed MP 35Tablets: 50 mg white, round, film coated, scored, debossed MP 542Tablets: 100 mg white, oval shape, film coated, scored, debossed MP 303Spironolactone tablets are contraindicated in the patients with:Spironolactone tablets can cause hyperkalemia. The mechanism of antiandrogenic activity of spironolactone is complex and appears to involve several effects of the drug. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and nephrotic syndrome. 70% were NYHA class III and 29% class IV. Doses greater than 100 mg/day generally do not provide additional reductions in blood pressure.In patients with cirrhosis, initiate therapy in a hospital setting and titrate slowly Administer Spironolactone tablets in doses of 100 to 400 mg daily in preparation for surgery. ), Spironolactone tablets were found to increase the length of the estrous cycle by prolonging diestrus during treatment and inducing constant diestrus during a two-week post-treatment observation period. Because of its antiandrogenic activity and the requirement of testosterone for male morphogenesis, Spironolactone tablets may have the potential for adversely affecting sex differentiation of the male during embryogenesis. No increased tumors were seen at doses of 100 mg/kg/day. Disease-Associated Maternal and/or Embryo/Fetal RiskFigure 1. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Spironolactone and any potential adverse effects on the breastfed child from Spironolactone or from the underlying maternal condition.Safety and effectiveness in pediatric patients have not been established.Spironolactone tablets are substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers Monitor serum potassium within 1 week of initiation or titration of Spironolactone tablets and regularly thereafter. Extra-renal effects of spironolactone.